Eli Lilly and Company

Eli Lilly

Jefferson Ray McCowan

Daniel Jon Sall

Gerald Floyd Smith

Ho-Shen Lin

Matthew Joseph Fisher

Minsheng Zhang

Richard Waltz Harper

Kumiko Takeuchi

Nickolay Y Chirgadze

Alan David Palkowitz

Michael Robert Wiley

Jolie Anne Bastian

Michael Enrico Richett

Robert J Foglesong

Mary George Johnson

Michael Lyle Denney

Michael P Lynch

Shawn Christopher Miller

Zhaogen Chen

Valentine Joseph Klimkowski

Jennifer Marie Tinsley

Todd Jonathan Kohn

John M Schaus

Thomas Daniel Aicher

Leonard Larry Winneroski, Jr

Ronald Jay Hinklin

Owen Brendan Wallace

Bruno Giethlen

Nancy June Snyder

James Ronald Gillig

Michael Philip Cohen

K Jeff Thrasher

James Lee Toth

Melvin J Yu

Nicholas J Bach

Thomas Edward Mabry

Mark Joseph Chicarelli

Timothy Alan Shepherd

Kenneth Jeff Thrasher

John Gordon Allen

Yanping Xu

John E Toth

Jeremy Schulenburg York

Robert Dean Dally

Jeffrey Thomas Mullaney

Zhipei Wu

Renhua Li

Gary A Hite

Timothy Barrett Durham

Hongqi Tian

Ashraf Saeed

Harold Burns Brooks

Kevin Robert Fales

Alexei Pavlovych Krasutsky

Chong Si

Kwame Frimpong

Frank George Njoroge

Jolie Ann Bastian

Gary Alan Hite

Junior Leonard Larry Winneroski

1-Oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as AICARFT inhibitors.

1-oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as AICARFT inhibitors in the treatment of cancers

The present invention discloses novel compounds of Formula I: possessing 11 &#x3b2;-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as methods of using the compounds and compositions to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, metabolic syndrome, cognitive disorders, and other conditions associated with 11 &#x3b2;-HSD type 1 activity. 

Biphenyl amide lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

The present invention provides compounds of formula (I), which are antagonists of the 5-HTreceptor. 

N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor

The present invention discloses compounds of Formula I: (I) having 11beta-HSD type 1 antagonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula I, as well as the use of the Formula I and compositions as medicaments to treat diabetes, hyperglycemia, obesity, hypertension, hyperlipidemia, Syndrome X, and other conditions associated with hyperglycemia. 

Cycloalkyl lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1

The present invention provides compounds of formula I pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are antagonists of the 5-HTreceptor. The present invention further provides a method of treating disorders associated with 5-HTreceptors, including schizophrenia, anxiety, Alzheimer's disease, and cognitive disorders selected from the group consisting of age-related cognitive decline, mild cognitive impairment, and dementia, comprising: administering to a patient in need thereof an effective amount of a compound of formula I.

[object Object]

The invention relates to novel compounds of formula (I), and their pharmaceutically acceptable salts, as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula (I), and the use of the compounds of formula (I) as thrombin inhibitors.

Antithrombotic agents

This application relates to novel compounds of formula I (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula I, and the use of defined compounds of formula I as thrombin inhibitors.

Thrombin inhibitors

This application relates to novel compounds of formula I (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula I, and the use of the compounds of formula I as thrombin inhibitors.

This application relates to novel compounds of formula (I) (and their pharmaceutically acceptable salts), as defined herein, processes and intermediates for their preparation, pharmaceutical formulations comprising the novel compounds of formula (I), and the use of the compounds of formula (I) as thrombin inhibitors.

Antithrombotic Agents

This application relates to the use as thrombin inhibitors, coagulation inhibitors and thromboembolic disorder agents of diamines of formula I as defined herein. It also provides novel compounds of formula I, processes and intermediates for their preparation, and pharmaceutical formulations comprising the novel compounds of formula I.

Antithrombotic diamines

This application relates to the use as thrombin inhibitors, coagulation inhibitors and thromboembolic disorder agents of heterocyclic derivatives of formula (I) as defined herein. It also provides novel compounds of formula (I), processes and intermediates for their preparation, and pharmaceutical formulations comprising the novel compounds of formula (I).

Growing community of inventors

Indianapolis, IN, United States of America

Jefferson Ray McCowan